ClinConnect ClinConnect Logo
Search / Trial NCT03268434

Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care

Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Aug 28, 2017

Trial Information

Current as of August 02, 2025

Completed

Keywords

Depression Metacognition Cbt D Mct Cognitive Bias

ClinConnect Summary

Evidence-based treatments for depression include pharmacological and psychological interventions. Within psychological interventions, cognitive behavioral therapy (CBT) is one of the most extensively researched evidence-based approaches for depression (Cuijpers, 2015). However, even if optimal treatment and access to services were available to all patients, the burden of depression would be reduced by only 30% (Andrews et al., 2004). Moreover, as depression represents the disorder with the highest drop-out rates during CBT treatment (36.4%) (Fernandez et al., 2015), and a relapse rate of 54...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • informed consent
  • age between 18 and 70 years
  • diagnosis of a single Episode or recurrent Major depressive disorder (MDD) or dysthymia (verified by the MINI)
  • Exclusion Criteria:
  • lifetime psychotic symptoms (i.e., hallucinations, delusions, or mania), suicidality (Suicidal Behaviors Questionnaire-Revised ≥ 7), intellectual disability (estimated IQ \< 70) or dementia.

About Universitätsklinikum Hamburg Eppendorf

Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.

Locations

Hamburg, , Germany

Patients applied

0 patients applied

Trial Officials

Marion Hagemann-Goebel, Dr.

Principal Investigator

Asklepios Klinik Nord-Ochsenzoll

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials